Liver Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Renewed drive vs. hepatitis B, liver cancer underway in SF Bay Area ... - Inquirer.net



Inquirer.net
 
Renewed drive vs. hepatitis B, liver cancer underway in SF Bay Area ... 
Inquirer.net
An unidentified elderly man gets himself screened for hepatitis B, a vaccine-preventable disease. CONTRIBUTED. SAN MATEO, California ? An intensified drive against hepatitis B and liver cancer is trying to raise public awareness of the single largest ...
Your liver is in trouble and you don't even realize it - Bel Marra Health Bel Marra Health

all 2 news articles » 


Merck's Keytruda shows treatment effect in mid-stage liver cancer study - Seeking Alpha



Finance News Daily
 
Merck's Keytruda shows treatment effect in mid-stage liver cancer study 
Seeking Alpha
Results from a Phase 2 clinical trial, KEYNOTE-224, assessing Merck's (NYSE:MRK) PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with advanced hepatocellular carcinoma who were previously treated with Bayer's NEXAVAR (sorafenib) showed a treatment ...
Merck & Company, Inc. (MRK) Zacks.com
X0306 4 2017-11-08 0000310158 Merck & Co., Inc. MRK 0001140799 GLOCER THOMAS H MERCK - SEC.gov SEC.gov
SEC FORM 4 - SEC.gov SEC.gov
SEC.gov 
all 98 news articles » 


AVEO Oncology's tivozanib shows positive effect in early-stage liver ... - Seeking Alpha



AVEO Oncology's tivozanib shows positive effect in early-stage liver ... 
Seeking Alpha
AVEO Oncology (AVEO +5.4%) is up on 30% higher volume in response to positive results from the Phase 1b portion of a Phase 1b/2 clinical trial assessing lead drug FOTIVDA (tivozanib) in patients with advanced unresectable hepatocellular carcinoma (HCC ...

and more » 


Investors unmoved with TRACON Pharma's TRC105 in mid-stage liver cancer study; shares down 7% - Seeking Alpha



Investors unmoved with TRACON Pharma's TRC105 in mid-stage liver cancer study; shares down 7% 
Seeking Alpha
Preliminary results from an ongoing Phase 1b/2 clinical trial assessing TRACON Pharmaceuticals' (TCON -6.6%) lead candidate TRC105, combined with Bayer's NEXAVAR (sorafenib), in patients with advanced hepatocellular carcinoma (HCC) demonstrated a ...

and more » 


Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results - Nasdaq



Labiotech.eu (blog)
 
Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results 
Nasdaq
Exelixis ( EXEL ) plunged Wednesday after Phase 3 data showed its liver cancer drug is comparable to a rival medicine from Bayer ( BAYRY ) - slightly below analyst expectations for better results. [ibd-display-video id=3088389 width=50 float=left ...
Investors unmoved by Exelixis' late-stage liver cancer data on cabozantinib; shares down 9% Seeking Alpha
Parisian Biotech's Drug Improves Liver Cancer Survival... But Not ... Labiotech.eu (blog)
Cabometyx trial halted early on success in liver cancer PharmaTimes
The Pharma Letter  -Zacks.com 
all 10 news articles » 


Smoking reduces survival after liver cancer diagnosis for people with viral hepatitis - aidsmap



Smoking reduces survival after liver cancer diagnosis for people with viral hepatitis 
aidsmap
People with viral hepatitis who smoked were three times more likely to die after being diagnosed with liver cancer (hepatocellular carcinoma, HCC), according to a study of Swiss patients published in Liver International. Whereas non-smokers lived for a ...

 


Cabozantinib phase 3 results show overall survival benefit for liver ... - Healio



Cancer Therapy Advisor
 
Cabozantinib phase 3 results show overall survival benefit for liver ... 
Healio
Exelixis and Ipsen announced results from the phase 3 Celestial trial of cabozantinib for hepatocellular carcinoma that showed significant overall survival benefit in patients previously treated for advanced HCC, according to a press release and data ...
Cabometyx Extends Survival in Liver Cancer Study Managed Care magazine
Cabometyx Extends Survival in Liver Cancer Study | P&T Community P&T Community

all 4 news articles » 


HCV liver cancer resection outcomes similar in patients with diabetes - Healio



HCV liver cancer resection outcomes similar in patients with diabetes 
Healio
Results of a comparative study of patients with and without diabetes who underwent curative liver resection for hepatitis C-related hepatocellular carcinoma showed that diabetes did not affect surgical outcomes and was not an unfavorable factor in ...

 


Dr. Abou-Alfa Discusses Treatment Options in Liver Cancer - OncLive



OncLive
 
Dr. Abou-Alfa Discusses Treatment Options in Liver Cancer 
OncLive
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in liver cancer. 2017 brought about the FDA approval of regorafenib (Stivarga) as a second-line treatment for patients with hepatocellular ...

 


Blood test promising to detect early cancers; Madison's Exact Sciences leader in field - Madison.com



Madison.com
 
Blood test promising to detect early cancers; Madison's Exact Sciences leader in field 
Madison.com
At the UW Carbone Cancer Center, Dr. Josh Lang called the Johns Hopkins cancer test ?an exciting technological development that is too early in the validation process.? Lang said ?the biggest flaw is ? they just haven't tested as many patients as they ...
Incredible New Test Could Provide Early Detection Of Eight Cancers IFLScience
Scientists Develop Single Blood Test That Detects Eight Common Cancers Genetic Engineering & Biotechnology News
Blood test for cancer gets a step closer - CNN - CNN.com CNN
New York Daily News  -Deutsche Welle  -Newsweek  -Science 
all 158 news articles »